Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Warrant (NQ:DRMAW)

0.0217 +0.0017 (+8.50%)
Streaming Delayed Price Updated: 1:04 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Via ACCESSWIRE
News headline image
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Via ACCESSWIRE
News headline image
Why Dermata Therapeutics Stock Took Off After-Hours ↗
Dermata Therapeutics, Inc. 
Via Benzinga
News headline image
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
News headline image
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Via ACCESSWIRE
News headline image
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
Via ACCESSWIRE
News headline image
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
Via ACCESSWIRE
News headline image
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc.... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.